Project Grant R01EY032994

Award Date 3/1/24
Completion Date 2/29/28
Dollars Obligated $1.6M
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Pasadena, CA 91103, USA
Similar Awards
This $673,747 Project Grant award from the National Eye Institute (NEI), under the NEI's Vision Research program (CFDA 93.867), will support the development of a novel visible-to-near-infrared spanning optical coherence tomography (OCT) system by researchers at New York University School of Medicine. The new OCT system aims to image depth-resolved macular pigments, retinal pigment epithelium melanosomes, and other outer retinal structural biomarkers with up to 0.5 micrometer axial resolution,...
The National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) awarded a $256,296 Project Grant (R21EY037019) to The General Hospital Corporation (Massachusetts General Hospital) to develop new optical coherence tomography angiography (OCTA) technology to improve the imaging of retinal microvasculature. The project aims to create a high-speed adaptive ranging OCTA system by leveraging advances in integrated photonics to expand the imaging depth range of OCTA,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Alabama at Birmingham (UAB) provides $583,558 in funding from September 30, 2024 to August 31, 2025. The project aims to investigate retinal manifestations of Alzheimer's disease (AD) through the following efforts: Tracking the earliest disease indicators in the APP/PS1 mouse model of AD using retinal testing techniques like electroretinography (ERG). Defining a range of normal...
This Project Grant award of $240,713.00 from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research focused on understanding the role of the nuclear-encoded humanin isoform MTRNR2L1 in the pathogenesis of age-related macular degeneration (AMD), a leading cause of blindness in the aging population. The research aims to elucidate whether MTRNR2L1 is a protein-encoding gene or a long non-coding RNA, and to explore its function in regulating...
This $433,841 federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the development of computational methods and deep learning models to analyze imaging data and identify biomarkers for age-related macular degeneration (AMD). The goal is to improve understanding of AMD disease progression and response to treatment. Specifically, the project will develop deep neural network models to analyze optical coherence tomography,...
The National Institute on Aging (NIA) awarded a $2,126,420 Project Grant (CFDA 93.866 - Aging Research) to The Trustees of the University of Pennsylvania to evaluate retinal imaging biomarkers that can distinguish frontotemporal lobar degeneration (FTLD) subtypes and differentiate FTLD from non-amnestic Alzheimer's disease. The 3-year project aims to use optical coherence tomography to identify retinal abnormalities that may serve as non-invasive biomarkers for the underlying tau, TDP-43, or...
The National Eye Institute (NEI), part of the National Institutes of Health, awarded a $331,131 Project Grant under the Vision Research program (CFDA 93.867) to Physical Sciences Inc. (PSI) to develop and validate a high-resolution retinal imaging system with light flicker capabilities. This system aims to enable objective characterization of the photoreceptor response to light and quantify differences between normal and diseased eyes, particularly for patients with diabetic retinopathy. PSI,...
The U.S. National Institute on Aging (NIA) awarded a $547,898 Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to The Research Foundation for The State University of New York (RF SUNY), which serves as the fiscal agent and sponsored programs administrator for the SUNY system. The goal of this 4-year project is to investigate the impact of sex on mitochondrial and epigenetic mechanisms in age-related macular degeneration (AMD), a leading cause of vision loss in older...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) to the Icahn School of Medicine at Mount Sinai provides $253,500 to develop an in vitro human outer blood-retina barrier (OBRB) model that can be used to investigate the role of ApoE variants in age-related macular degeneration (AMD). The project aims to optimize the OBRB system to reliably induce AMD-like pathological hallmarks, such as drusen formation, and then leverage this model to evaluate how...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $531,670 to The Leland Stanford Junior University to assess the feasibility of a dietary intervention study for individuals with early-stage age-related macular degeneration (AMD). The key objectives are to: Demonstrate the feasibility of transitioning participants from a typical Western diet to a low-glycemic, Mediterranean diet. Evaluate the feasibility of obtaining sensitive retinal imaging and...

IN VIVO IMAGING OF THE HUMAN RETINA AT THE MOLECULAR LEVEL - PROJECT SUMMARY THE FLUORESCENCE LIFETIME MEASURES THE DURATION A FLUOROPHORE REMAINS EXCITED BEFORE RETURNING TO THE GROUND STATE BY EMITTING A PHOTON. IT IS AN INTRINSIC PROPERTY UNIQUE TO EACH FLUORESCENT MOLECULE AND ITS ENVIRONMENTAL STATE. FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY (FLIO) CAN PERFORM IN VIVO LIFETIME MEASUREMENTS OF ENDOGENOUS SIGNALS IN THE RETINA AND RETINAL PIGMENT EPITHELIUM (RPE), RANGING FROM VITAMIN A DERIVATIVES IN LIPOFUSCIN (LF) TO FLAVIN-ADENINE-DINUCLEOTIDE (FAD) IN MITOCHONDRIA. AS MANY FLUORESCENT MOLECULES HAVE BEEN IMPLICATED IN AGING AND AGE-RELATED MACULAR DEGENERATION (AMD), FLIO PROMISES PRECISE MEASUREMENTS OF THE METABOLIC STATUS AND OXIDATIVE STRESS LEVELS IN RETINAL LAYERS/CELLS. WITH THREE SPECIFIC AIMS, WE PROPOSE TO DEVELOP CELLULAR-LEVEL FLIO. FIRST, WE WILL MARRY FLIO WITH STATE-OF-ART ADAPTIVE OPTICS (AO) TO OVERCOME THE EYE'S OPTICAL IMPERFECTIONS AND CREATE ADAPTIVE OPTICS (AO) ENHANCED FLIO (AOFLIO). WE WILL DEVELOP AOFLIO ON AN AO SCANNING LASER OPHTHALMOSCOPE (AOSLO), A RETINAL IMAGING INSTRUMENT WITH PROVEN CELLULAR RESOLUTION. THE AOFLIO INSTRUMENT WILL ACHIEVE DIFFRACTION-LIMITED IMAGE RESOLUTION (~2 MM LATERAL, ~ 30 MM AXIAL) OVER A 7o X 7o FOV IN A SINGLE FRAME; THIS IS ~21 TIMES LARGER THAN THAT OF THE CURRENT AOSLO. FURTHER, WE WILL FORTIFY AOFLIO WITH NOVEL IMAGE-PROCESSING STRATEGIES TO QUANTITATIVELY RESOLVE THE COMPLEX MIX OF COLORS AND LIFETIMES OF RETINAL AND RPE FLUOROPHORES. THE IMPROVED PROCESSING CAPABILITIES OF PHASOR ANALYSES OF FLUORESCENCE LIFETIMES WILL PERMIT SUPERIMPOSED SIGNALS FROM MULTIPLE MOLECULAR SPECIES TO BE UNMIXED AND PERMIT IMAGING WITH A MEAGER LIGHT BUDGET. WE WILL LEVERAGE RECENT ADVANCES IN THE HISTOLOGY OF THE HUMAN RETINA AND RPE FOR IN VIVO ANALYSES USING FLIO TO MEASURE FLUOROPHORES WITHIN INDIVIDUAL CELLS, SPECIFIC LAYERS, AND SUBCELLULAR STRUCTURES. THUS, AOFLIO PROMISES THE COMBINED SPEED AND RESOLUTION WITH AN ADEQUATE FIELD OF VIEW (FOV) TO OFFER A NEEDED WINDOW INTO RETINAL FUNCTION IN NORMAL PHYSIOLOGY AND DISEASE. SECOND, WE WILL CHARACTERIZE AND DISTINGUISH FLUORESCENCE SIGNALS WITH HIGH SPATIAL PRECISION IN NORMAL HUMAN SUBJECTS AND ESTABLISH A NORMATIVE DATABASE OF FLUORESCENCE LIFETIMES IN DIFFERENT RETINAL LAYERS AND INDIVIDUAL (PHOTORECEPTOR AND RPE) CELLS IN HUMAN SUBJECTS OF AGE, GENDER, AND RACE/ETHNICITY, THEREBY FACILITATING CORRELATION WITH LEADING CANDIDATES FOR SIGNAL SOURCES. THIRD, WE WILL USE AOFLIO TO CHARACTERIZE THE METABOLIC FUNCTION OF THE RETINAL PIGMENT EPITHELIUM (RPE) IN AMD, A DISEASE THAT CAUSES VISION LOSS IN OVER 10 MILLION OLDER AMERICANS. OUR STUDY WILL FOCUS ON INTRARETINAL HYPERREFLECTIVE FOCI (IHRF), THE STRONGEST PREDICTOR OF THE DEVELOPMENT OF LATE AMD, AND INVESTIGATE FUNDAMENTAL QUESTIONS OF IHRF PATHOGENESIS AND ITS ROLE IN THE PATHOPHYSIOLOGY OF AMD. THESE AIMS WILL HELP US IMPROVE RETINAL AND RPE METABOLIC FUNCTION ASSESSMENT IN NORMAL AGING AND AMD. THE ACHIEVEMENT WILL PROVIDE A FOUNDATION FOR FUTURE INVESTIGATION OF THE PATHOPHYSIOLOGY OF A BROAD ARRAY OF RETINAL AND CENTRAL NERVOUS SYSTEM DISEASES FOR WHICH AGING IS A RISK FACTOR.

Posted 2/21/24, 12:00 AM